ID-KORE-POWER/CLEANHILL
29.6.2021 14:02:12 CEST | Business Wire | Press release
KORE Power, Inc., (“KORE Power” or “KORE”) the leading U.S.-based developer of battery cell technology for the energy storage and electric transportation industries, announced that it has formed a strategic partnership with Cleanhill Partners (“Cleanhill”), a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. Cleanhill has invested in KORE Power as part of the strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005233/en/
Rakesh Wilson and Ash Upadhyaya, founders of Cleanhill, have joined KORE Power as special advisors to Founder and CEO Lindsay Gorrill. As veterans of the energy finance and investment sector, Rakesh and Ash will guide KORE’s strategy on growth and investment opportunities.
“Rakesh and Ash bring over 40 years of combined experience in ESG, power, energy and infrastructure,” said CEO Lindsay Gorrill. “We are excited to partner with them to tap into their rich experience to position KORE as the leader in the energy transition sector.”
Ash Upadhyaya is a founder and Managing Partner at Cleanhill Partners. He has over 20 years of experience in private equity and engineering, focusing on the energy value chain. Ash was a Managing Director at Centerbridge Partners and a Director at KKR. He has engineering degrees from Stanford University and the University of Mumbai and an MBA from Stanford University.
“I’m thrilled to work with KORE Power to expand the design and manufacturing of lithium-ion battery cells in the U.S.,” said Ash. “Through my experience with energy storage, I see the critical role that batteries will play in the clean energy transition. I look forward to adding value to KORE’s expert team.”
Rakesh Wilson has over 20 years of energy finance and private equity experience and is a founder and Managing Partner at Cleanhill Partners. He previously served as a Senior Partner at Apollo Global Management and led private equity investments across the energy value chain. Rakesh was also with Morgan Stanley’s Commodities Division and Goldman Sachs’ investment banking and equity research divisions. He graduated from the University of Texas at Austin and received his MBA from INSEAD, Fontainebleau, France.
“Working with KORE Power is a natural extension of my work on battery storage projects, renewable infrastructure, distributed generation, energy trading funds and carbon offsets,” said Rakesh. “The lithium-ion cell is at the center of the clean energy future, and I look forward to accelerating the clean energy transition by working with KORE.”
Evercore served as financial advisor to KORE Power and Kirkland & Ellis LLP served as legal counsel to Cleanhill Partners.
ABOUT KORE Power
KORE Power, Inc., is a leading US-based developer of battery cell technology for the clean energy industry, serving energy storage, e-mobility, utility, industrial and mission-critical markets across the globe. KORE Power designs and manufactures its proprietary NMC and LFP cells, VDA modules and packs, optimized by the battery management system. Through its global partnerships, KORE designs and manufactures top-tier energy storage systems (ESS).
KORE Power’s differentiated approach provides customers with direct access, unparalleled service, superior technology, and Tier 1 product availability. We care about building sustainable communities, clean energy jobs and green economic expansion. KORE Power is proud to offer a functional solution to real-world problems that fulfill growing market demand and contribute to a zero-carbon future. For more information, visit www.korepower.com .
ABOUT Cleanhill Partners
Cleanhill Partners is a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. We invest in scalable businesses with visibility into revenues, earnings and cash flow growth. We leverage our thesis-driven approach and our operational expertise to enhance value in each of our investments. Our long-term investment philosophy to decarbonize and create value aligns our stakeholders, our communities and the businesses we invest in. The firm has offices in New York and Houston. To learn more, please visit www.cleanhillpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom